NCT02039128已完成不适用
A Double-blind, Randomized, Placebo-controlled Study to Assess Changes in the Omega-3 Index in Erythrocytes After Twelve Weeks of Daily Intake of SuperbaTM Krill Oil or Fish Oil
Aker BioMarine Human Ingredients AS1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2014年1月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Change in relative amount of EPA and DHA in erythrocytes
研究概览
简要总结
In this double blind, placebo controlled, parallel group study, the relative uptake of 1g/d krill oil in comparison to 1g/d fish oil in healthy female and male adults will be assessed.
Primary objective is to determine if a 12 week supplementation with krill oil increases tissue levels in erythrocytes (omega-3 index) significantly more than fish oil after dose adjustments to EPA and DHA levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent
- •Be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the Investigator
- •Be in general good health with no existing co-morbidities
- •Be aged between 20 and 50 years
- •Both genders allowed (at least 40% of each gender to be recruited into the study)
- •Have a body mass index (BMI) between 19 and 30 kg/m² (extremes included)
- •Have a omega-3 index in erythrocytes of <6.2% at screening
- •Have clinically normal findings for haematology and clinical chemistry (or clinically insignificant, if value is outside of the normal range)
- •Be willing to maintain dietary habits and physical activity levels throughout the trial period (next 12 weeks)
- •Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less (a list of fish and seafood considered to be fatty is provided to volunteers)
- •Be willing to avoid all fish and seafood meals in the 3 days before each scheduled clinic visit
- •Be willing to avoid alcohol in the 24 hours before each scheduled clinic visit
- •Be willing to avoid sportive activity in the 24 hours before each scheduled clinic visit
- •Be willing to complete questionnaires, records and diaries associated with the study
排除标准
- •Diseases or disorders that include: Rheumatoid arthritis, chronic serious illness, cardiovascular problems, liver and kidney disease, diabetes, endocrine or metabolic disease, inflammatory bowel disease, pancreatitis, gallbladder or biliary disease, neurological or psychological disease, bleeding disorders, experiences platelet abnormalities, gastrointestinal disorders that could interfere with fat absorption, acute and history of cancer, HIV, hepatitis B or C, an intention to lose weight
- •Pregnant or nursing women or women of child-bearing potential whose urinary pregnancy test at screening is positive
- •Postmenopausal women
- •Known allergy to crustaceans (shellfish) or fish
- •Known alcohol or drug abuse within the previous year of screening
- •More than 20 alcohol Units per week
- •Clinically significant illness within 3 days prior to dosing (fever; inability to work etc.)
- •Donation of blood or similar blood loss within the previous 30 days before screening
- •Participation in a clinical trial with an investigational product within 90 days before screening
- •Present or recent use (within 3 months of screening) of any medication which is a known lipid modifying agent
- •Present or recent use (within 3 months of screening) of dietary supplements that affect the level of blood cholesterol and triglycerides, such as fish oil supplements, niacin, etc
- •Patients with known coagulopathy or receiving anticoagulant therapy or co-morbidity that would interfere with the study results
- •Frequency of fatty fish and/or seafood consumption is greater than twice per month
- •Present or recent use (within 3 months of screening) of any long-chain omega-3 or omega-6 fatty acid supplement
研究组 & 干预措施
Krill oil
Experimental
1 gram per day in 12 weeks
干预措施: Krill oil or Fish oil (Dietary Supplement)
Fish oil
Active Comparator
1 gram per day in 12 weeks
干预措施: Krill oil or Fish oil (Dietary Supplement)
Placebo
Placebo Comparator
1 gram per day in 12 weeks
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
Change in relative amount of EPA and DHA in erythrocytes
时间窗: Baseline to Week 12
次要结局
- Number of participants with Adverse Events as a Measure of Safety and Tolerability(Baseline to Week 12)
- Change in relative amount of EPA and DHA in erythrocytes(Baseline to Week 6)
- Blood lipid status(Baseline to Week 12)
- Quality of Life(Baseline to week 12)
- Mood Scores by a Likert Scale(Baseline to week 12)
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Topical Palm Tocotrienols on Skin Biophysical PropertiesWrinkleNCT05787743Universiti Sains Malaysia41
已完成
不适用
A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese AdultsGastrointestinal DysfunctionNCT05820737Vedic Lifesciences Pvt. Ltd.155
终止
不适用
Topical Palm Tocotrienols on Blemish-prone SkinAcneNCT05756881Universiti Sains Malaysia5
已完成
不适用
A Study to Evaluate the Efficacy of E-PR-01 on Musculoskeletal Health in Physically Active IndividualsJoint PainNCT05825222Vedic Lifesciences Pvt. Ltd.157
已完成
2 期
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With DiabetesEfficacySafetyPharmacokineticsDiabetes Mellitus, Type 2NCT05353686Pila Pharma54